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Abstract
OBJECTIVE—This study examined changes in survival among children with Down syndrome 
(DS) by race/ethnicity in 10 regions of the United States. A retrospective cohort study was 
conducted on 16 506 infants with DS delivered during 1983–2003 and identified by 10 US birth 
defects monitoring programs. Kaplan-Meier survival probabilities were estimated by select 
demographic and clinical characteristics. Adjusted hazard ratios (aHR) were estimated for 
maternal and infant characteristics by using Cox proportional hazard models.
RESULTS—The overall 1-month and 1-, 5-, and 20-year survival probabilities were 98%, 93%, 
91%, and 88%, respectively. Over the study period, neonatal survival did not improve appreciably, 
but survival at all other ages improved modestly. Infants of very low birth weight had 24 times the 
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risk of dying in the neonatal period compared with infants of normal birth weight (aHR 23.8; 95% 
confidence interval [CI] 18.4–30.7). Presence of a heart defect increased the risk of death in the 
post-neonatal period nearly fivefold (aHR 4.6; 95% CI 3.9–5.4) and continued to be one of the 
most significant predictors of mortality through to age 20. The postneonatal aHR among non-
Hispanic blacks was 1.4 (95% CI 1.2–1.8) compared with non-Hispanic whites and remained 
elevated by age 10 (2.0; 95% CI 1.0–4.0).
CONCLUSIONS—The survival of children born with DS has improved and racial disparities in 
infant survival have narrowed. However, compared with non-Hispanic white children, non-
Hispanic black children have lower survival beyond infancy. Congenital heart defects are a 
significant risk factor for mortality through age twenty.
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Down syndrome; survival; mortality; congenital heart defects; epidemiology; low birth weight; 
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Down syndrome (DS) is the most common chromosomal disorder among live births and 
occurs in 1 in every 700 live births in the United States.1 DS is associated with premature 
mortality and an increased risk for a number of co-morbid conditions including cardiac, 
gastrointestinal, musculoskeletal or orthopedic, ear and hearing, ophthalmic, endocrine, 
leukemia, and autism.2 Even though trends in the total birth prevalence of DS have been 
difficult to determine because of the lack of reliable data on trends in the number of DS-
related fetal deaths, the birth prevalence of DS has increased in recent decades in the United 
States and many other countries.3,4 These trends are due in part to an increasing proportion 
of births to women over age 35.3,4
Although the survival probability for children with DS has improved in recent years,5,6 the 
overall fatality among infants with DS remains more than 5 times higher than that of general 
population.7,8 Furthermore, there is evidence that survival is lower for black children with 
DS than for white children with DS; however, the reason for the higher fatality rates among 
blacks is unknown.7–10 Factors associated with premature mortality among infants and 
children with DS include the presence of congenital heart defects (CHD), other structural 
malformations,6,9,10 leukemia,7 and low birth weight.9,11 Whether variations in the 
prevalence of these risk factors among race/ethnicity groups explain the observed 
differences in survival is unclear.
In this study, we examined the long-term trends in survival for children with DS and the 
variation in survival probabilities by maternal and infant characteristics based on data from 
10 population-based surveillance programs in the United States. Adjusted hazard ratios 
(aHRs) were estimated to assess the association between possible prognostic factors and 
mortality.
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METHODS
Data Sources and Case Criteria
Infants born with DS were identified by 10 population-based birth defects monitoring 
programs located in Arkansas, Georgia (5 central counties of metropolitan Atlanta*), 
California (11 counties†), Colorado, Iowa, New York (New York City excluded), North 
Carolina, Oklahoma, Texas, and Utah. The birth cohorts available for each program were 
Arkansas, 1993–2002; Georgia, 1983–2003; California, 1983–2002; Colorado, 1989–2003; 
Iowa, 1983–2003; New York, 1983–2003; North Carolina, 1989–1993, 1995–2003; 
Oklahoma, 1994–2003; Texas, 1996–2003; and Utah, 1995–2003. Vital status was 
ascertained for all births with DS through December 31, 2004, for all of the regions except 
for Arkansas and California, the follow-up periods of which ended on December 31, 2003, 
and December 31, 2002, respectively. Infants with karyotype diagnosis of trisomy 21 were 
classified as DS by using a modified British Paediatrics Association (BPA) coding system in 
most regions except for New York, where infants with DS were classified by both BPA and 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes, and in the regions of North Carolina and Colorado, where they were classified by 
ICD-9-CM codes only. Deaths among children with DS were ascertained by linkage with 
medical records, state vital records, and the National Death Index.3
Children with DS and no death records were considered alive at the end of the study follow-
up period and treated as censored observations in the survival analysis. Demographic and 
clinical characteristics of infants with DS from birth were also collected by the surveillance 
programs. Infants of <500 g, <20 weeks of gestational age, or with unconfirmed diagnosis of 
DS were excluded from our study.
Both demographic and clinical characteristics were included as potential risk factors for 
survival of infants with DS including maternal race/ethnicity (non-Hispanic white, non-
Hispanic black, Hispanic, and other), maternal age (<35 years vs ≥35 years), maternal 
education (<12 years, ≥12 years), sex, birth weight (<1500 g, 1500–2499 g, ≥2500 g), and 
region. Infants with DS were classified as having a major CHD if their records indicated the 
presence of ICD-9-CM or BPA codes for CHD (745.000–747.430 and 747.640). Codes for 
normal physiologic findings in newborns or premature infants (eg, patent foramen ovale, 
patent ductus arteriosus), minor conditions such as tricuspid insufficiency, or unconfirmed 
cardiac defects were not considered structural heart defects.
Data Analysis
The survival probabilities at 1 month, 1 year, 5 years, 10 years, and 20 years were estimated 
by the Kaplan-Meier product-limit method.12 Greenwood’s method was used to calculate 
the variance of the estimated survival probability and their 95% confidence intervals (CIs).13 
For those study regions with at least 20 years of follow-up (GA, CA, IA, and NY), the infant 
survival probabilities and 95% CIs were estimated for 4 birth cohorts (1983–1987, 1988–
*Clayton, Cobb, DeKalb, Fulton, and Gwinnett.†San Francisco and Santa Clara (1983–2003); Stanislaus (1984–2003); Merced (1985–2003); Fresno, Tulare, and San Joaquin (1986–
2003); Kern, Kings, and Madera (1987–2003); Los Angeles (1990–2003, excluding 1998).
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1992, 1993–1997, 1998–2003), and a trend analysis for the increasing survival over birth 
cohorts across race/ethnicity was conducted.
A log-rank test was used to determine whether the survival probabilities were significantly 
different among various levels of potential demographic and clinical risk factors.14 Cox 
proportional hazard models were used to estimate unadjusted and adjusted hazard ratios 
(aHR) for possible prognostic factors.14 The assumption of proportionality for the hazards 
was checked by plotting estimated log-cumulative hazard versus log of survival time for 
different categories of the risk factors. Possible time-dependent trends were also tested to 
confirm the assumption of proportionality. Final multivariate proportional hazard models 
were obtained, and the aHRs were estimated for the significant covariates. For the 
multivariate proportional hazard models, aHRs were estimated assuming survival through 
the preceding age period. Computations were performed by using SAS-PC (version 9.13; 
SAS Institute Inc, Cary, NC), and figures were generated by using S-PLUS (version 6.0; 
Insightful Corp, Seattle, WA). This study was approved by the Institutional Review Board 
of the Centers for Disease Control and Prevention.
RESULTS
From 1983 to 2003, 16 506 liveborn infants with DS were identified in the 10 regions 
included in our study. The number of infants ascertained in the regions ranged from 362 in 
Arkansas to 4686 in California with a median number of 982 infants, and the period of 
follow-up ranged from 9 years in Texas to 22 years in Georgia, Iowa, and New York (Table 
1). Among those with comparable follow-up time (11 years), the regional variation was 
greatest between Arkansas (87.2%) and Utah (90.7%; P = .01).
The overall 1-month and 1-, 5-, and 20-year survival probabilities were 98%, 93%, 91%, and 
88%, respectively (Tables 2 and 3), with the highest mortality occurring in the postneonatal 
period. Over the 20-year study period, neonatal survival did not improve appreciably, but 
modestly improved survival at older ages was observed for those infants with DS born after 
1996 (Table 4).
Univariate analysis demonstrated that survival varied by a number of demographic and 
maternal characteristics (Table 2 and 3). The greatest variation in survival to 1 year of age 
was by birth weight. Infants with normal birth weight had a 95% survival to 1 year 
compared with 56% and 90% survival to infants of very low and low birth weight, 
respectively. Infants born with a CHD had lower infant survival than those without (90% vs 
96%). Infants born to non-Hispanic black and non-Hispanic white mothers had nearly 
identical neonatal survival, but thereafter infants to non-Hispanic black mothers experienced 
increasingly lower survival through age 20 (Fig 1). When stratified by birth weight, infants 
of non-Hispanic black mothers had lower overall survival only among normal and low birth 
weight (1500–2499 g) infants; among very low birth weight infants (<1500 g), infants of 
non-Hispanic black mothers had higher survival than infants of either non-Hispanic white or 
Hispanic mothers.
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Restricting the cohort period to the years during which all regions contributed case data 
(1997–2003), the pooled survival probability to 1 year was 94% (Fig 2). The 1-year survival 
probability ranged from 92% in Arkansas to 96% in Utah (P = .02). For the regions with ≥20 
years of follow-up (GA, CA, IA, and NY), an increasing trend of survival across 4 birth 
cohort periods was detected (P = .002) overall and for each region except for the region of 
Georgia (data not shown). Trends of improving survival were apparent across the 4 time 
periods for each major racial/ethnic groups: non-Hispanic white (P = .0002), non-Hispanic 
black (0.0117), and Hispanic (0.0002); however, the greatest improvement in 1-year survival 
trends was among infants with a major CHD or of birth weight <2500 g (Fig 3).
For those infants with no missing values for the covariates included in the Cox proportional 
hazard models (n = 16 418), factors associated with an increased risk of death for children 
with DS were race/ethnicity, maternal age, birth weight, multiple births, and presence of 
CHD (Table 4). The only factor associated with an increased risk of neonatal death was birth 
weight. Infants of very low birth weight had 24 times the risk of dying compared with 
infants of normal birth weight (aHR 23.8; 95% CI 18.4–30.7), and infants of low birth 
weight had nearly 2.5-fold increased risk (aHR 2.4; 95% CI 1.8–3.2). Among those who 
survived the neonatal period, birth weight continued to be associated with an increased risk 
for death by age 1 for very low (aHR 1.9; 95% CI 1.7–2.3) and low (aHR 6.9; 95% CI 5.6–
8.6) birth weight infants. The presence of a heart defect increased the risk of death in the 
postneonatal period nearly fivefold (aHR 4.6; 95% CI 3.9–5.4) and continued to be one of 
the most significant predictors of mortality through age 20. The aHR among non-Hispanic 
blacks at age 1 was 1.4 (95% CI 1.2–1.8) compared with non-Hispanic whites and increased 
to 2.0 (95% CI 1.0–4.0) by age 10. Infants born to Hispanic mothers had a lower aHR at 1 
month of age (aHR 0.8; 95% CI 0.6–1.0) and had an overall reduced risk for mortality (aHR 
0.8; 95% CI 0.7–0.9) compared with infants born to non-Hispanic white mothers.
DISCUSSION
Survival among individuals with DS has improved in the United States over time, and 
survival to 1 year now averages 94% among the 10 regions included in this study. With the 
exception of the neonatal period, survival in the United States improved over time for all age 
points, and the most significant gains were among infants born of low birth weight or with a 
major CHD. Although slight racial and ethnic disparities in survival persist, these have 
decreased markedly over time. Survival estimates to 1 year varied from 92% to 96% among 
the 10 regions included in the study. Reasons for state variation are unclear but might be the 
result of different population characteristics, variations in case ascertainment, state-level 
policies governing eligibility criteria for health care coverage, or variations in the amount 
and type of public services available.
This is the largest population-based survival study for people with DS using birth defects 
surveillance programs, which provide a unique source of quality data ascertained from 
multiple sources for high sensitivity and diagnostic accuracy in the United States. Previous 
survival estimates in the United States have been limited to individual surveillance 
programs.9,15,16 Data for most of those studies were subsumed by this study to produce the 
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most nationally representative survival estimates available to date that can serve as a 
benchmark as well as a comparison point for reports from other countries.
Linkage of surveillance data with the National Death Index ensured the most accurate 
determination of the vital status of children even if they died out of state and adds 
significantly to the credibility of the findings17; however, the assumption that a child was 
alive if there was no record of death found from the three data sources could be a potential 
limitation of the study. Additionally, no information on surgeries, clinical management, or 
barriers to health care as potential contributors to the long-term survival of children with DS 
was examined.
Factors most associated with an increased risk of mortality among individuals with DS were 
race/ethnicity, low birth weight, and the presence of CHD. Although some studies have 
suggested a survival advantage among male children,6,18 our study confirmed findings from 
other studies that found no survival differences by sex9,10,19–21 Although previous reports 
have found an increased risk associated with low birth weight,6,9,21 only 1 other population-
based study was found that examined very low birth weight infants (<1500 g) as a distinct 
group, possibly because of relatively low study population sizes.22 This study found that 
among infants with very low birth weight those with DS had 2.5 times the risk of death 
compared with very low birth weight infants with no birth defects. The percent of infants 
with DS in our study population that were born with birth weight <2500 g was 22%, a >2.5-
fold increased risk compared with the general population, and these infants were twice as 
likely to be born <1500 g.23 Recognition of the high risk of mortality associated with very 
low birth weight for infants with DS is important to increase vigilance among health care 
providers for this vulnerable group.
Two previous reports in the United States were inconsistent with regard to racial and ethnic 
disparities in survival9,15; however, the discrepancy is likely the result of 2 study attributes. 
First, each used non overlapping time periods of observation, so that the later study 
(Vendola et al) might reflect the narrowing survival gap as evidenced by the decreasing 
trend in disparities seen in this study. The second and more compelling reason for the 
differences in the study findings was that Rasmussen et al presented overall hazard ratios up 
to 20 years of age, whereas Vendola et al restricted their analysis to the first year of life. Our 
study showed that association between race and mortality increased with increasing age.
Several studies observed that the greatest black-white disparity occurred among infants with 
no major CHD, suggesting that more undiagnosed CHD among non-Hispanic blacks might 
be contributing to the disparity.8,9,24,25 Non-Hispanic black infants without a CHD had 
lower 1-year survival than non-Hispanic whites from 1983 to 1989 (91.3% vs 95.8%), but 
the disparity nearly disappeared by the 1997–2003 period (97.4% vs 97.7%). To evaluate the 
potential role of undiagnosed CHD in the black-white disparity, we examined the percent of 
infants with DS and a CHD by race and over time. During both the earliest and most recent 
time periods, a greater percent of non-Hispanic blacks with DS was diagnosed with a heart 
defect compared with non-Hispanic whites: 44% among non-Hispanic blacks versus 41% 
among non-Hispanic whites during 1983–1989 and 53% among non-Hispanic blacks versus 
50% among non-Hispanic whites during 1997–2003. Furthermore, although less severe 
Kucik et al. Page 6
Pediatrics. Author manuscript; available in PMC 2015 August 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CHD such as muscular ventricular septal defects are reported less frequently among non-
Hispanic blacks compared with non-Hispanic whites,26 there appear to be little racial/ethnic 
difference in the birth prevalence of more severe heart defects that would have a greater 
influence on survival, such as atrioventricular septal defect, the most common heart defect 
among infants with DS.26,27
Unique to this study was the examination of the changing impact across the life span of 
factors that contribute to mortality. Goldman et al found age variations in the contribution by 
specific factors to mortality, but the study was limited to the first year of life.22 Our analysis 
showed that very low and low birth weight conferred the greatest risk of mortality during the 
neonatal period, but the associated risk lessened with increasing age. CHDs are the leading 
cause of death among infants with DS8 and conferred a risk of mortality that was highest 
during the post-neonatal period and was associated with the greatest risk relative to the other 
factors from age 1 through 10. The mortality risk associated with non-Hispanic black race 
increased with increasing age even after adjusting for the presence of a heart defect and low 
birth weight, possibly reflecting inadequate access or utilization of health care services.
The population-based approach of this study is a substantial strength in that it ensures the 
most complete live-born population of infants with DS. The limitation of this and most 
survival studies is the lack of accounting for the prenatal experience. Attitudes toward 
prenatal testing and the use of it vary by a number of maternal factors, including 
sociodemographic factors, race, and ethnicity.28 The proportion of elective terminations of a 
fetus with DS in the United States ranged from 7% to 37% with variations by time period 
and regional racial/ethnic composition.29–32 A recent review of population-based studies of 
pregnancies with a positive prenatal diagnosis of DS estimated that 67% of pregnancies 
were terminated, but a temporal analysis found that the proportion of electively terminated 
pregnancies has consistently decreased in recent years.33 Although information on 
frequency of termination is scarce and difficult to interpret,34,35 evidence suggests that 
elective terminations might have a significant impact on the epidemiology of live born 
infants with DS.36,37 If the presence of severe comorbid conditions such as major CHD 
factor into the decision to terminate, the observed decreasing trends in the decision to 
terminate a pregnancy with a positive diagnosis of DS could be the result of more fetuses 
with less complicated health profiles being carried to term. This potential scenario would 
lead to a live birth population with an overall higher likelihood of survival, but the extent to 
which this might contribute to the recent improvements in survival among children with DS 
is not clear.
Survival in the United States compares favorably for both short- and long-term survival of 
individuals with DS. The 93% infant survival in the United States was higher than that 
reported in the United Kingdom (88%),38 Australia (92%),6 Ireland (88%),20 Italy (80%),21 
and Denmark (85%).39 The 10-year survival of 91% in the United States was also higher 
than estimates elsewhere, which ranged from 82% to 85%,6,20,37 and the 20-year survival 
rate of 88% was higher than reported elsewhere.37 International comparisons should be 
made with some caution because differences in ascertainment methods, the time period of 
observation, and disposition for elective terminations could account for some of the 
observed differences in infant survival.4,40 However, comparison of the longer-term survival 
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estimates that are likely to be less affected by such factors can become particularly 
important in planning for health services to address specialized health and social services 
needs of children, adolescents, and adults with DS. In particular, about half of children with 
DS have major comorbid conditions such as CHD for which access to timely and quality 
health care services is critically important not only for survival but also to ensure a 
reasonable quality of life.
CONCLUSIONS
Survival of individuals with DS has improved over the past 20 years, and the racial and 
ethnic disparities have diminished, particularly during infancy, potentially as the result of 
improved access to health care services; however, non-Hispanic blacks still appear to be at 
greater risk of mortality throughout childhood and adolescence. Improved surgical and 
medical management of CHD and issues related to low birth weight have contributed to the 
overall improved survival of those with DS, yet significant risks are still associated with 
these factors. Population-based survival analyses to date have been limited to the evaluation 
of demographic and clinical factors present at birth. Linkage of population-based birth 
defects surveillance data with additional data sources such as hospital discharge data would 
provide a powerful tool to examine the impact of health care access, quality, and utilization 
on health outcomes of individuals with DS.
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WHAT’S KNOWN ON THIS SUBJECT
Although survival of children born with Down syndrome has improved, unexplained 
racial and ethnic disparities in survival persist in the United States.
WHAT THIS STUDY ADDS
This study used population-based data from 10 birth defects monitoring programs in the 
United States to examine survival trends among children born with Down syndrome and 
to evaluate the changing influence of survival predictors over the life course.
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FIGURE 1. 
Kaplan-Meier survival curves by race and ethnicity and birth weight for individuals born 
with DS in from 10 US regions, 1983–2003.
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FIGURE 2. 
Survival probability to 1 year among children with DS, 1997–2003.
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FIGURE 3. 
Racial/ethnic variation in one year survival of children with Down syndrome in four states/
regions (CA, GA, IA, NY) by select clinical characteristics, 1983–2003.
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TABLE 1
Sample Size and Years of Observation by Region in Ascending Order of Years of Follow-up
Region Sample Size Birth Years Follow-up Years Years of Follow-up
Texas 2663 1996–2003 1996–2004 9
Utah 556 1995–2003 1995–2004 10
Arkansas 362 1993–2002 1993–2003 11
Oklahoma 546 1994–2003 1994–2004 11
Colorado 972 1989–2003 1989–2004 16
North Carolina 1628 1989–1993, 1995–2003 1989–2004 16
California 4686 1983–2002 1983–2003 20
Iowa 849 1983–2003 1983–2004 22
New York 3355 1983–2003 1983–2004 22
Georgia 889 1983–2003 1983–2004 22
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